Complement Inhibitor Dosing for CAD Surgery Hemolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with cold agglutinin disease (CAD) face a significant risk of hemolysis and complications during major surgeries, particularly cardiac surgery, due to complement activation, which can lead to severe hemolytic exacerbations and exclusion from elective procedures without effective preventive measures.
Innovation Solution
Maintaining a therapeutic serum concentration of a proximal classical complement pathway inhibitor, such as sutimlimab, before, during, and after surgery to reduce or prevent hemolysis in CAD patients, through administration of maintenance doses and assessing serum concentrations to ensure effective inhibition of the complement pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If CAD patients undergo major surgery, then surgical treatment can be provided, but hemolysis is exacerbated and hemoglobin levels drop significantly
Solution Approach 1:
The patent applies preliminary anti-action by administering complement pathway inhibitors (such as eculizumab or ravulizumab) to CAD patients before major surgery. This pre-treatment suppresses complement activation in advance, preventing the harmful hemolytic effects that would otherwise occur during surgery. The inhibitor is maintained at therapeutic levels through dosing schedules optimized to cover the surgical period, thereby blocking the complement-mediated hemolysis pathway before it can be activated by surgical stress.
Solution Approach 2:
The patent implements preliminary action by establishing therapeutic serum concentrations of complement inhibitors prior to surgery and maintaining them throughout the surgical period. This involves administering loading doses followed by maintenance doses to ensure adequate drug levels are present before the surgical stressor occurs, allowing the patient to undergo surgery safely without experiencing exacerbated hemolysis.
2Object-affected harmful factors
If complement pathway inhibitors are administered to prevent hemolysis, then hemolytic events are reduced, but drug dosage and monitoring complexity increase
Solution Approach 1:
The patent applies parameter changes by establishing specific therapeutic serum concentration ranges for complement pathway inhibitors that are effective at preventing surgery-associated hemolysis. The invention identifies and recommends specific dosing regimens (loading doses followed by maintenance doses) that achieve and maintain these therapeutic parameters. By defining clear concentration targets and dosing schedules, the patent simplifies the complexity of dosage management while ensuring effective hemolysis prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach safely and efficiently reduces or prevents surgery-associated hemolysis in CAD patients, minimizing complications and allowing for the performance of major surgeries without exacerbating hemolytic events.
Implementation Method 1
maintaining in the subject a therapeutic serum concentration of a proximal classical complement pathway inhibitor (e.g., a C1s inhibitor, such as sutimlimab)... effective to reduce or prevent hemolysis
Data Source
AI summary
Provided herein are methods for reducing or preventing surgery-associated hemolysis in subjects who have cold agglutinin disease (CAD) (e.g., been diagnosed with CAD or have had at least one symptom of CAD).